University of Washington

Point-Counterpoint: Oncotype Dx Genomic Prostate Score in Active Surveillance – Canary PASS Study

Point-Counterpoint: Oncotype Dx Genomic Prostate Score in Active Surveillance – Canary PASS Study

| Apr 2020

Daniel W. Lin, MD, and Eric A. Klein, MD, present a point-counterpoint on the conclusions of Dr. Lin’s recently published results of Canary PASS (Prostate Active Surveillance Study), which looked at the ability of the Oncotype DX genomic prostate score (GPS) for predicting adverse pathology (AP) in primarily low-risk prostate cancer patients undergoing active surveillance. Following each presentation, Dr. Lin and Dr. Klein also discuss several follow-up questions related to the study and, more broadly, the future of prostate cancer treatment with E. David Crawford, MD, Editor-in-Chief of Grand Rounds in Urology.

Read More
Molecular Insights into the Germline for Prostate Cancer Initiation, Progression, and Aggressiveness

Molecular Insights into the Germline for Prostate Cancer Initiation, Progression, and Aggressiveness

| Jan 2020

Colin C. Pritchard, MD, PhD, director of the Genetics and Solid Tumors Laboratory at the University of Washington Medical Center, discusses how germline testing and next-generation sequencing (NGS) of tumors have become important for guiding prostate cancer diagnosis, treatment, and assessment of risk. He details DNA damage response (DDR) genes, including key pathways, potential risk factors, and general characteristics. He also discusses the role of molecular pathologists in testing samples, choosing methodology, and interpreting results.

Read More
Genomic Markers and DNA Sequencing Testing

Genomic Markers and DNA Sequencing Testing

| Oct 2018

Daniel W. Lin, MD, reviews novel and emerging biomarkers across the spectrum of prostate cancer. He then explains an emerging model of prostate cancer treatment with genomic markers and DNA sequencing, discussing newly-identified precision targets and their therapeutic decision-making utility.

Read More